CTAP TFA
| 产品介绍 | CTAP TFA 是一种强效、高选择性的、可透过血脑屏障的阿片受体 (μ opioid receptor) 拮抗剂,IC50 为 3.5 nM。CTAP TFA 对 δ opioid 受体 (IC50=4500 nM) 和生长抑素受体 (somatostatin receptors) 具有超过 1200 倍的选择性。CTAP TFA 可用于L -多巴胺 (HY-N0304) 诱导的运动障碍 (LID) 和阿片类活性分子过量或成瘾的研究。 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 生物活性 | CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC50 of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction. | ||||||||||||||||
| 体外研究 | |||||||||||||||||
| 体内研究 |
CTAP TFA (0-1 mg/kg, IP, single) blocks morphine’s antinociceptive effect. 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||||||||||
| 体内研究 |
CTAP TFA (0-1 mg/kg, IP, single) blocks morphine’s antinociceptive effect. 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||||||||||
| 性状 | Solid | ||||||||||||||||
| 溶解性数据 |
In Vitro:
H2O : 100 mg/mL (82.08 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 | ||||||||||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
| 储存方式 |
Sealed storage, away from moisture and light, under nitrogen
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen) | ||||||||||||||||
| 参考文献 |
|

浙公网安备 33010802013016号